Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma
10 mars 2022 08h30 HE
|
Allogene Therapeutics, Inc.
ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which Has Broad Potential Application Across a Variety of Solid Tumors and Hematologic MalignanciesPhase 1 TRAVERSE Trial of ALLO-316...
Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report
01 mars 2022 08h30 HE
|
Allogene Therapeutics, Inc.
Comprehensive Report Highlights Efforts to Advance Diversity, Equity and Inclusion, Sustainable Business Practices, and Corporate Governance SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
23 févr. 2022 16h02 HE
|
Allogene Therapeutics, Inc.
AlloCAR T™ Studies Resumed and Currently Enrolling Patients Following Removal of Clinical Hold in January 2022Phase 1 Data from the ALPHA Trials in Relapsed/Refractory (RR) Non-Hodgkin Lymphoma...
Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022
16 févr. 2022 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
26 janv. 2022 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
11 janv. 2022 08h00 HE
|
Allogene Therapeutics, Inc.
miCAR Platform Enables Simultaneous Silencing of Multiple Gene TargetsAllogene to Deploy miCAR and other Technologies to Create the Next Generation of Allogeneic Cell Products SOUTH SAN FRANCISCO,...
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
10 janv. 2022 08h30 HE
|
Allogene Therapeutics, Inc.
Investigation Confirmed the Chromosomal Abnormality in a Single Patient was Not Observed in Any AlloCAR T Product and Not Related to Allogene Manufacturing Process or TALEN® Gene EditingClinical...
Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
15 déc. 2021 08h30 HE
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
13 déc. 2021 11h00 HE
|
Allogene Therapeutics, Inc.
ALLO-715 UNIVERSAL Trial is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety and Substantial Efficacy in Multiple Myeloma Updated Data Demonstrate Responses Similar to Approved Autologous...